Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

8 days required by the inclusion criteria.

A total of 87 percent of patients in the placebo group completed treatment, as did 82 percent, 77 percent, and 62 percent in the 200, 400, and 600 mg/day Vimpat(R) groups.

Summary of Vimpat(R) Data Presented at 2008 AES Annual Meeting

Early Onset of Efficacy in the Initial Weeks of Treatment with Lacosamide: A Pooled Analysis of Three Phase II/III Trials

This analysis found that Vimpat(R) demonstrated statistically significant efficacy as early as the first week of treatment, with consistently significant results for both primary endpoints starting at doses of 100 mg/day.

-- At the end of the first week of treatment in this study, when all participants in the active treatment groups were receiving 100 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (33.0 percent Vimpat(R) group vs. 19.4 percent placebo; p<.01). Also during the first week, 39.1 percent of patients treated with Vimpat(R) experienced a 50 percent or greater reduction in seizures, compared with 31.3 percent in the placebo group (p<.01).

-- By the end of the second week of treatment, when all participants in the treatment groups were receiving 200 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (34.0 percent Vimpat(R) group vs. 20.0 percent placebo; p<.01). The percentage of patients with a 50 percent or greater reduction in seizure frequency was 40.2% for patients receiving Vimpat(R) and 32.2 percent for placebo (p<.01 vs. placebo).

-- These significant seizure reductions appeared to be maintained over subsequent weeks of Vimpat(R) treatment.


    Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.256)
    Michael Sperling, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty,
     PhD
    Thomas Jefferson Universit
'/>"/>
SOURCE  UCB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... City, CA (PRWEB) May 20, 2013 ... has announced the appointment of Lisa Baird as Executive ... on July 8, 2013. The WMIS vision ... imaging applications to understand and effectively treat diseases in ... Imaging Society (WMIS) was established in 2011 by integrating ...
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine and ... Albert Einstein College of Medicine and Associate Chairman of ... He is also Associate Director for Clinical Research ... Breast Cancer Working Group, a multidisciplinary group of physicians ... also serves as Vice Chair of the National Cancer ...
(Date:5/17/2013)... Amsterdam, May 17, 2013 - Elsevier, a world-leading provider ... today announced the publication of a recent study in ... old human blastocysts showing that those with an abnormal ... which they have developed to blastocysts, thereby classifying the ... new study the same group has undertaken a retrospective ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
Breaking Biology Technology:WMIS Appoints Lisa Baird as Next Executive Director 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... MIGENIX Inc. (the,"Company" or "MIGENIX") (TSX: MGI; ... infectious diseases, reports financial results for the ... a corporate update on its programs,and other ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic ...
... decades-old drug to beat atherosclerotic plaques in research conducted ... , The scientists have found that drug-laced nanoparticles plus ... vessels that feed arterial plaques. Their results suggest that ... their growth, which could shrink or stabilize plaques. Although ...
... safe supply of drinking water for regions of the ... is rife. Writing in the International Journal of ... nanotubes could replace conventional materials in water-purification systems. , ... water will continue to grow as major global problems. ...
Cached Biology Technology:MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11Old and new therapies combine to tackle atherosclerosis 2Old and new therapies combine to tackle atherosclerosis 3Water purification down the nanotubes 2
(Date:5/16/2013)... The relationship between the heritable risk for schizophrenia ... Schizophrenia is commonly associated with cognitive impairments that ... reduced IQ may be linked to the risk ... may precede the onset of schizophrenia symptoms. Also, ... of people diagnosed with schizophrenia. , In a ...
(Date:5/16/2013)... extinct creature with ,scissor hand-like, claws in fossil records ... movie star. , The 505 million year old ... which is a distant ancestor of lobsters and scorpions, ... starring role as Edward Scissorhands - a movie about ... has scissors for hands. , Kooteninchela deppi ...
(Date:5/16/2013)... genome-wide analysis (GWA), where the entirety of an individual,s ... or variants which can cause health problems is a ... can also pose major ethical problems if used incorrectly, ... Genetics (ESHG) published on line today (16 May 2013) ... Many services based on whole genome and on exome* ...
Breaking Biology News(10 mins):Genetic risk for schizophrenia is connected to reduced IQ 2Actor Johnny Depp immortalized in ancient fossil find 2European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... The University of Queensland could contribute to the development ... and Dengue fever. Led by Associate Professor ... of Molecular and Microbial Sciences identified a novel characteristic ... The team found all flaviviruses produced a ...
... to a radical re-thinking about how the snowy owl ... the adult females that we followed in a satellite ... the Arctic sea ice," said Universit Laval doctoral student ... as part of an International Polar Year (IPY) research ...
... LANSING, Mich. --- Research by a Michigan State University ... way of developing protein-based drugs that are key to ... hepatitis. Proteins used in drug manufacture and research ... , a one-cell bacteria. That protein tends to collect ...
Cached Biology News:UQ research targets West Nile virus and dengue fever 2Snowy owl -- a marine species? 2
WD-repeat protein 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
... Cultured human omental preadipocytes ... but otherwise healthy donors. ... of diabetic cells. Please ... Support media also available. ...
ASCIZ...
Biology Products: